Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1995 1
1999 1
2001 4
2003 3
2004 3
2005 2
2006 4
2007 3
2008 4
2009 3
2010 9
2011 6
2012 14
2013 4
2014 10
2015 10
2016 8
2017 3
2018 7
2019 8
2020 1
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 25961464

100 results
Results by year
Filters applied: . Clear all
Page 1
Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.
McVeigh TP, Jung SY, Kerin MJ, Salzman DW, Nallur S, Nemec AA, Dookwah M, Sadofsky J, Paranjape T, Kelly O, Chan E, Miller N, Sweeney KJ, Zelterman D, Sweasy J, Pilarski R, Telesca D, Slack FJ, Weidhaas JB. McVeigh TP, et al. Cell Cycle. 2015;14(13):2091-9. doi: 10.1080/15384101.2015.1041694. Epub 2015 May 11. Cell Cycle. 2015. PMID: 25961464 Free PMC article.
A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.
Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, Kerin M, Zelterman D, Zhu Y, Tuck D, Harris L, Miller N, Slack F, Weidhaas J. Paranjape T, et al. Lancet Oncol. 2011 Apr;12(4):377-86. doi: 10.1016/S1470-2045(11)70044-4. Epub 2011 Mar 22. Lancet Oncol. 2011. PMID: 21435948 Free PMC article.
Estrogen and breast cancer: can less mean more?
Bullock MD, Silva AM, Calin GA. Bullock MD, et al. Cell Cycle. 2015;14(14):2197-8. doi: 10.1080/15384101.2015.1056617. Epub 2015 Jun 19. Cell Cycle. 2015. PMID: 26090587 Free PMC article. No abstract available.
The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer.
Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP. Pilarski R, et al. PLoS One. 2012;7(5):e37891. doi: 10.1371/journal.pone.0037891. Epub 2012 May 25. PLoS One. 2012. PMID: 22662244 Free PMC article.
Association of a let-7 KRAS rs712 polymorphism with the risk of breast cancer.
Huang X, Yang Y, Guo Y, Cao ZL, Cui ZW, Hu TC, Gao LB. Huang X, et al. Genet Mol Res. 2015 Dec 14;14(4):16913-20. doi: 10.4238/2015.December.14.19. Genet Mol Res. 2015. PMID: 26681038 Free article.
The KRAS-variant and its impact on normal breast epithelial cell biology.
Jung SY, Malhotra P, Nguyen KC, Salzman D, Qi Y, Pak EH, King J, Vlashi E, Ann D, Weidhaas JB. Jung SY, et al. Cell Death Differ. 2019 Dec;26(12):2568-2576. doi: 10.1038/s41418-019-0320-y. Epub 2019 Apr 1. Cell Death Differ. 2019. PMID: 30932013
Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
Uvirova M, Simova J, Kubova B, Dvorackova N, Tomaskova H, Sedivcova M, Dite P. Uvirova M, et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Sep;159(3):466-71. doi: 10.5507/bp.2015.029. Epub 2015 Jun 11. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015. PMID: 26077004 Free article.
Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.
Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, Look M, Collee JM, Nieuwlaat A, Dorssers LC, Seynaeve C, Aulchenko YS, Martens JW, van den Ouweland AM, Weidhaas JB. Hollestelle A, et al. Breast Cancer Res Treat. 2011 Jul;128(1):79-84. doi: 10.1007/s10549-010-1080-z. Epub 2010 Jul 30. Breast Cancer Res Treat. 2011. PMID: 20676756 Free PMC article.
KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study.
Cerne JZ, Stegel V, Gersak K, Novakovic S. Cerne JZ, et al. BMC Cancer. 2012 Mar 22;12:105. doi: 10.1186/1471-2407-12-105. BMC Cancer. 2012. PMID: 22436609 Free PMC article.
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB. Ratner ES, et al. Oncogene. 2012 Oct 18;31(42):4559-66. doi: 10.1038/onc.2011.539. Epub 2011 Dec 5. Oncogene. 2012. PMID: 22139083 Free PMC article.
100 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback